4/A: Avanos Medical Amends Executive Stock Option Grant

Avanos Medical, Inc. filed an amended Form 4 to correct an error in the calculation of stock options granted to SVP of Operations, Sigfrido Delgado.

Summary

• This filing is an amendment (Form 4/A) to a previously filed Form 4, correcting an error in the calculation of stock options issued to Sigfrido Delgado, SVP of Operations.
• The original transaction date for the awards was March 13, 2026.
• Sigfrido Delgado acquired 15,886 Time-Based Restricted Share Units (TRSUs) at a price of $0, which are the economic equivalent of one share of Common Stock each.
• These TRSUs will vest in three tranches: 1/3 on March 13, 2027, 1/3 on March 13, 2028, and 1/3 on March 13, 2029.
• Sigfrido Delgado also acquired 37,782 employee stock options with an exercise price of $13.69.
• These stock options will vest in three tranches: 30% on March 13, 2027, 30% on March 13, 2028, and 40% on March 13, 2029, and have an expiration date of March 13, 2036.
• All awards were granted pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended.
• Following these reported transactions, Sigfrido Delgado beneficially owns 60,005 shares of Common Stock directly and 59,696 derivative securities (employee stock options) directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, primarily an administrative correction to an executive compensation filing, with no direct impact on the company's operational or financial performance.

Positives

• The grant of 15,886 Time-Based Restricted Share Units (TRSUs) to SVP of Operations, Sigfrido Delgado, aligns executive interests with long-term shareholder value.
• The grant of 37,782 employee stock options provides a long-term incentive for the executive, linking compensation to future company performance.

Negatives

• An administrative error in the initial calculation of stock options required an amendment to the filing, indicating a minor internal reporting issue.

Risks

• Potential for administrative errors in executive compensation reporting, though corrected in this instance, could lead to temporary inaccuracies in public disclosures.

Future Outlook

The vesting schedules for the Time-Based Restricted Share Units and employee stock options extend through March 13, 2029, indicating a long-term incentive structure designed to retain and motivate the SVP of Operations.

Management Comments

• The filing was signed by John Hurley, acting as attorney-in-fact for Sigfrido Delgado.

Industry Context

StockSavvy.ai notes that executive equity grants, such as restricted stock units and stock options, are standard practice across industries to align management incentives with long-term shareholder value. The amendment itself is an administrative correction, which is not uncommon in complex compensation reporting for publicly traded companies.

Comparison to Industry Standards

• The use of time-based restricted share units (TRSUs) and employee stock options is a common compensation strategy for senior executives in publicly traded companies, similar to practices at peers like Medtronic or Stryker, aiming to foster long-term commitment and performance.
• The vesting schedule, spanning three years, is typical for long-term incentive plans, comparable to those seen in the broader medical device sector.

Stakeholder Impact

• Shareholders: Minor impact from an administrative correction; the underlying executive incentive structure remains in place, aligning management with long-term shareholder interests.
• Employees: No direct impact on general employees, but reinforces the company's long-term incentive plan for executives.

Next Steps

• The first tranche of Time-Based Restricted Share Units and employee stock options will vest on March 13, 2027.
• The second tranche of Time-Based Restricted Share Units and employee stock options will vest on March 13, 2028.
• The final tranche of Time-Based Restricted Share Units and employee stock options will vest on March 13, 2029.

Key Dates

Recommendation

This filing is an administrative amendment correcting an error in an executive's stock option grant. It does not provide new material information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. The underlying executive compensation structure remains consistent with long-term incentive practices.

Keywords

AVNS, Avanos Medical, SEC Form 4, insider transaction, stock options, restricted stock units, executive compensation, Sigfrido Delgado, long-term incentive plan